Proton Pump Inhibitors Affect Atezolizumab Efficacy in Advanced NSCLC

Proton Pump Inhibitors Affect Atezolizumab Efficacy in Advanced NSCLC

The use of immune checkpoint inhibitors (ICIs) has improved the survival of patients with advanced non-small cell lung cancer (NSCLC) markedly, although...

Achieving Organ Preservation in LA Rectal Cancer: The Role of Total Neoadjuvant Therapy

Achieving Organ Preservation in LA Rectal Cancer: The Role of Total Neoadjuvant Therapy

The standard treatment for patients with locally advanced (LA) rectal adenocarcinoma is neoadjuvant chemoradiotherapy (CRT), total mesorectal excision (TME), and adjuvant chemotherapy....

First-Line Anti-PD1 Plus Chemotherapy Combo Justified in Advanced Nasopharyngeal Cancer

First-Line Anti-PD1 Plus Chemotherapy Combo Justified in Advanced Nasopharyngeal Cancer

Nasopharyngeal cancer (NPC) is a rare disease in Western countries, while in Southeast Asia the incidence is high. Most patients are diagnosed...

FDA Approvals for Cancer Management in the First Quarter of 2022

FDA Approvals for Cancer Management in the First Quarter of 2022

In Quarter 1 of 2022, the FDA approved seven new indications for cancer management, with March being a near-record month with five...

Triplet Combo Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer

Triplet Combo Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer

Treatment options for patients with metastatic, hormone-sensitive prostate cancer (mHSPC) are rapidly changing. The standard of care systemic therapy for these patients...

Some Oncogene Drivers Impact Efficacy of Durvalumab Consolidation in Stage III NSCLC

Some Oncogene Drivers Impact Efficacy of Durvalumab Consolidation in Stage III NSCLC

The standard of care for patients with unresectable locally advanced (stage III) non-small cell lung cancer (NSCLC) is definitive chemoradiotherapy (CRT) followed...